Sanofi NV (NASDAQ:SNY) has been flexing its biotech muscles, and investors are taking notice. The stock is firmly in bullish territory, recently forming a Golden Cross, a classic technical signal that often precedes further gains.
With momentum traders piling in and Sanofi's latest Dupixent breakthrough adding serious fuel to the rally, the stock is in the spotlight.
Sanofi Stock Chart Screams Bullish
Chart created using Benzinga Pro
Sanofi stock is up 21.89% year-to-date. Its eight-day, 20-day, 50-day and even 200-day moving averages all point higher.
The stock also completed a Golden Cross, where the 50-day moving average crosses above the 200-day moving average, a signal that typically indicates a long-term uptrend.
The MACD (moving average convergence/divergence) indicator sits at 1.77, another bullish signal, while an RSI (relative strength index) of 69.91 puts it just on the edge of overbought territory – suggesting the rally might still have room to run.
Read Also: Top 3 Health Care Stocks That May Keep You Up At Night In Q1
Dupixent's Big Moment
The real game-changer? Sanofi's blockbuster drug Dupixent just posted strong Phase 2/3 trial results for treating bullous pemphigoid (BP).
The drug improves disease remission and reduces severity. It also cut the need for corticosteroids—potentially setting the stage for a first-of-its-kind treatment.
With regulatory submissions under review in the US and EU, the FDA has granted priority review, with a decision expected by June 2025.
If approved, Dupixent could tap into yet another lucrative market, further cementing its blockbuster status.
With a Golden Cross reinforcing its bullish momentum and a major FDA decision looming, investors are watching closely—because this rally might just be getting started.
Read Next:
Image: Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
